Shots:
- ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW
- The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio with innovative ADC and combines ImmunoGen’s lead clinical program with Huadong’s regional oncology expertise
- Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a FRα binding antibody, cleavable linker & the maytansinoid DM4 to kill the targeted cancer cells
Click here to read full press release/ article | Ref: ImmunoGen | Image: PNGitem
The post ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China first appeared on PharmaShots.
